Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-avibactam pharmacokinetics and clinical outcomes in severe carbapenem-resistant gram-negative infection
ChiCTR2500101318Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Apr 2025
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ceftazidime + avibactam in Carbapenem-resistant Gram-negative bacterial infection (CRGNB), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoints: Blood routine examination, Blood biochemistry and 6 more. Started Apr 2025; status: recruiting.
02
Drugs
ceftazidime + avibactam
03
Conditions
Carbapenem-resistant Gram-negative bacterial infection (CRGNB)
Beyond the preview
Go deeper on ChiCTR2500101318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101318.